KOPRAN
|
The Current P/E Ratio of KOPRAN is 54.57.
| Share Price | ₹282.3 | Oct 01,2026 |
| Market Cap | ₹1,363.3 Cr | |
| Earnings-TTM | ₹25.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 54.57x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of KOPRAN
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,363.3 Cr] as on Oct 01,2026
(/) Earnings [ ₹25.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 54.57x ]
Thus, for KOPRAN , the investors are currently willing to pay 54.57 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of KOPRAN !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of KOPRAN over the last five years.
Historical PE (Price/Earnings) ratio chart of KOPRAN
PE Ratio Performance Analysis for KOPRAN
- KOPRAN 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 21.68x.
- KOPRAN 's operated at median p/e ratio of 21.93x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, KOPRAN 's p/e ratio peaked in Mar2024 at 24.45x.
- KOPRAN 's p/e ratio hit its five-year low in Mar2023 of 19.55x.
How does KOPRAN 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| KOPRAN | 24.98 | 54.57 | 1,363.3 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 35.68 | 434,280.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 84.35 | 246,737.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 84.01 | 181,129.0 |
| CIPLA LTD | 3,364.84 | 32.34 | 108,808.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.61 | 100,170.0 |
| MANKIND PHARMA LTD | 2,055.11 | 50.79 | 104,376.0 |
| LUPIN LTD | 5,551.01 | 16.71 | 92,784.1 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.43 | 114,239.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.96 | 96,375.8 |
| LAURUS LABS LTD | 1,090.76 | 98.53 | 107,468.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs KOPRAN 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 16.71x |
| Max industry PE | 98.53x |
| Median industry PE | 35.68x |
| Average industry PE | 49.09x |
You may also like the below Video Courses